Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data

finance.yahoo.com/news/evercore-downgrades-intellia-ntla-despite-094516710.html

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Evercore ISI downgraded Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In Line and cut its price target to $8 from $17, citing uncertainty around the…

This story appeared on finance.yahoo.com, 2025-11-18 09:45:16.
The Entire Business World on a Single Page. Free to Use →